Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Oct. 5 — Hologic's products for detecting the presence of cancers and HIV/AIDS in clinical samples infringe an Enzo Life Sciences Inc. patent, Enzo alleged Oct. 3 in federal district court ( Enzo Life Sciences, Inc. v. Hologic, Inc., D. Del., No. 1:16-cv-00894, filed 10/3/16 ).
Enzo, which is based in New York, asserted in the U.S. District Court for the District of Delaware that Hologic's “capture” technology in its Progensa PCA3, Aptima and Procleix products infringes Enzo's U.S. Patent No. 6,221,581. Enzo asked the court for a jury trial, damages, “enhanced” damages because the infringement was willful, attorneys' fees and costs and an order that Enzo get a compulsory ongoing licensing fee.
The lawsuit is the latest in a series of both court and agency litigation between Enzo and Hologic in the competitive market of genetic testing, in one of which Enzo sued Hologic and 10 other life sciences companies. Depending on how the market is defined, analysts such as Grand View Research Inc. and Mordor Intelligence estimate that the global value of the genetic testing market will range from $10 billion to $25 billion by 2022.
Both Enzo and Hologic declined Bloomberg BNA's request for comment about Enzo's Oct. 3 lawsuit. In response to a question as to whether the new litigation might grow to resemble that of 2012, an Enzo spokesman told Bloomberg BNA in an Oct. 5 e-mail: “We have not as yet filed similar suits, and are not commenting as to whether the company plans to do so.”
While Enzo's new lawsuit is for infringement of a patent for finding genetic mutations and defects, Enzo sued 11 life sciences companies, including Hologic, in separate 2012 lawsuits for infringement of its patents for genetic identification and testing (10 LSLR 15, 7/22/16). Five of the 11 companies have reached settlements with Enzo. Six, including Hologic, haven't, and the lawsuits against them are ongoing.
Enzo also filed litigation in 2015 in the federal district court in Delaware alleging that Hologic's Progensa PCA3, Aptima and Procleix infringed a different Enzo patent, U.S. Patent No. 7,064,197. The litigation has been stayed pending the outcome of the 2012 lawsuit. On March 30, 2016, Hologic filed a petition for the Patent and Trademark Office's Patent Trial and Appeal Board to potentially invalidate the '197 patent.
Hologic's global diagnostic product revenue was $1.2 billion in its FY 2015, according to its annual report, and $903 million for the first nine months of FY 2016, according to its July 27 filing with the Securities and Exchange Commission. The life sciences segment of Enzo's parent company Enzo Biochem had global 2015 annual revenues of $15 million, according to Enzo Biochem's annual report.
Enzo Life Sciences wrote in its complaint that its '581 patent discloses novel processes useful for separating or isolating nucleic acids of interest from samples. One such process comprises forming a multi-hybrid complex comprising a nucleic acid strand of interest, a second nucleic acid strand that is fixed or immobilized to a solid support, and a third nucleic acid strand that is capable of forming hybrids with both the nucleic acid of interest and the nucleic acid fixed or immobilized to the solid support.
According to Enzo's complaint, the result of the Hologic “target capture” approach that is used in Progensa PCA3, Aptima and Procleix is a multihybrid complex that is fixed to a magnetic microparticle and comprises three nucleic acid strands: the nucleic acid of interest or target, the capture oligomer, and the oligonucleotide fixed on the magnetic microparticles.
Enzo alleged that Hologic knowingly infringed the '581 patent. Hologic clearly knew about that patent because it referenced it in applications for five subsequently issued patents, Enzo stated.
The complaint was filed by Farnan LLP, Wilmington, Del., with Desmarais LLP, New York, of counsel.
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
The complaint is at http://src.bna.com/i9Q.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)